Recent reporting and commentary featuring Americans for Safe and Effective Medicines.
ASEM Chief Policy Officer Fred Mills, PharmD., cautions that growing demand for compounded peptides is outpacing the scientific evidence on their safety, effectiveness, dosing, and quality.
Read coverageASEM Chief Policy Officer Fred Mills, PharmD., comments on FDA advisory committee's recommendation to allow compounding of several peptides, cautioning that the decision could repeat the patient safety issues seen with mass-compounded GLP-1s.
Read coverageASEM Chief Policy Officer Fred Mills, PharmD., examines how illegal mass compounding has moved beyond patient-specific care, creating new risks for consumers and undermining trust in legitimate pharmacy compounding.
Read coverageA look at ASEM's launch and its call for stronger enforcement against illegal mass compounding, highlighting concerns about misleading marketing and the continued production of knockoff GLP-1 products.
Read coverageAn overview of ASEM's launch and its survey findings on compounded GLP-1s, highlighting widespread patient confusion about FDA approval
Read coverage